| 6.42 -0.14 (-2.13%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.93 | 1-year : | 8.72 |
| Resists | First : | 6.79 | Second : | 7.46 |
| Pivot price | 6.47 |
|||
| Supports | First : | 5.71 | Second : | 4.75 |
| MAs | MA(5) : | 6.6 |
MA(20) : | 6.55 |
| MA(100) : | 7.88 |
MA(250) : | 6.34  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 51.1 |
D(3) : | 53.7 |
| RSI | RSI(14): 42 |
|||
| 52-week | High : | 10.41 | Low : | 3.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DMAC ] has closed above bottom band by 44.2%. Bollinger Bands are 44.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.55 - 6.58 | 6.58 - 6.61 |
| Low: | 6.21 - 6.25 | 6.25 - 6.29 |
| Close: | 6.35 - 6.42 | 6.42 - 6.48 |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Sat, 18 Apr 2026
Companies Like DiaMedica Therapeutics (NASDAQ:DMAC) Are In A Position To Invest In Growth - simplywall.st
Mon, 30 Mar 2026
DiaMedica Therapeutics Inc. - Common Stock (DMAC) Stock Price, News, Quote & History - FinancialContent
Mon, 30 Mar 2026
DM199 pipeline: DiaMedica Therapeutics (NASDAQ: DMAC) targets stroke and preeclampsia - Stock Titan
Mon, 30 Mar 2026
DMAC: Advanced clinical programs and raised capital, maintaining a strong cash runway through 2H 2027 - TradingView
Mon, 30 Mar 2026
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights - Business Wire
Mon, 23 Mar 2026
DiaMedica schedules March 31 call for 2025 results, business update - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 27.7 (%) |
| Held by Institutions | 38.4 (%) |
| Shares Short | 4,590 (K) |
| Shares Short P.Month | 4,150 (K) |
| EPS | -0.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40 % |
| Return on Equity (ttm) | -67.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -9.18 |
| PEG Ratio | 0 |
| Price to Book value | 6.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|